Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: May 16, 2022
Reporting Period: The filing references a press release containing financial information for the quarter ended March 31, 2022. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only indicates that such information was issued in a press release on May 16, 2022.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the press release information is being furnished to the SEC and shall not be deemed incorporated by reference into any registration statements.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Guidance: No forward-looking guidance is included in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 16, 2022) for the actual Q1 2022 financial results, as they are not embedded in this summary text.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbols ADIL (Common Stock) and ADILW (Warrants) on NASDAQ.
- Note that the financial data in the referenced press release is not incorporated by reference into other SEC filings.